Quince Therapeutics (QNCX) Total Liabilities (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Total Liabilities of $11.0 million for Q1 2026, down 87.63% year-over-year from $88.5 million in Q1 2025, and down 91.53% quarter-over-quarter from $129.2 million in Q4 2025.
Quince Therapeutics (QNCX) Total Liabilities (2018 - 2026) Analysis & Trends
Quince Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $11.0 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 87.63% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (down 87.63% YoY), while the FY2025 annual figure was $129.2 million, up 53.25% from the prior year.
- Total Liabilities for Q1 2026 stood at $11.0 million, down from $129.2 million in the prior quarter.
- The five-year high for Total Liabilities was $129.2 million in Q4 2025, with the low at $2.0 million in Q2 2023.
- The 5-year median for Total Liabilities is $81.6 million (2024), against an average of $52.7 million.
- The sharpest annual moves came in 2024 and 2026: Total Liabilities soared 4401.08% in 2024, then slumped 87.63% in 2026.
- Quince Therapeutics' Total Liabilities stood at $3.3 million in 2022, then jumped by 2396.71% to $82.8 million in 2023, then gained by 1.83% to $84.3 million in 2024, then jumped by 53.25% to $129.2 million in 2025, then sank by 91.53% to $11.0 million in 2026.
- Business Quant data shows QNCX's Total Liabilities at $11.0 million in Q1 2026, $129.2 million in Q4 2025, and $108.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 15.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.95 Mn |
| Dec 31, 2025 | 129.24 Mn |
| Sep 30, 2025 | 108.84 Mn |
| Jun 30, 2025 | 105.47 Mn |
| Mar 31, 2025 | 88.51 Mn |
| Dec 31, 2024 | 84.33 Mn |
| Sep 30, 2024 | 81.59 Mn |
| Jun 30, 2024 | 87.86 Mn |
| Mar 31, 2024 | 85.12 Mn |
| Dec 31, 2023 | 82.82 Mn |
| Sep 30, 2023 | 2.25 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | 3.12 Mn |
| Dec 31, 2022 | 3.32 Mn |
| Sep 30, 2022 | 5.25 Mn |
| Jun 30, 2022 | 6.33 Mn |
| Mar 31, 2022 | 9.75 Mn |
| Dec 31, 2021 | 14.64 Mn |
| Sep 30, 2021 | 14.76 Mn |
| Jun 30, 2021 | 19.31 Mn |